MedImmune

MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca and is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease.

Address: Milstein Building, Granta Park , Cambridge
Postcode: CB21 6GH
Country: United Kingdom
Website: http://www.medimmune.com
Membership type:Founder Member

MedImmune is the global biologics research and development arm of AstraZeneca with candidate biologics and vaccines that currently compromise approximately 50 per cent of AstraZeneca’s overall R&D pipeline.   It has one of the most robust and promising pipelines in the biologics industry, with more than 120 biologics in research and development and over 40 projects in clinical stage development.

MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease. In addition, the company is opportunistic in infectious disease and vaccines. Approximately 2,200 full-time employees are in the US and UK. MedImmune is headquartered in Gaithersburg, MD – one of AstraZeneca’s three global R&D centres, along with Cambridge, UK and MoIndal, Sweden

MedImmune’s Cambridge team is focused on the research and early development of our biologics portfolio. MedImmune has built on the local legacy of Cambridge Antibody Technology (CAT) – acquired by AstraZeneca and integrated with MedImmune in 2007 – where three marketed products (Humira, Benlysta and raxibacumab) were invented.  With over 600 employees, MedImmune Cambridge has strong collaborative links with numerous academics, researchers, foundations and neighbouring companies in the largest biotech cluster in Europe and has an active outreach programme within the local community.

1 Humira is a registered trademark of AbbVie Inc.
2 Benlysta is a registered trademark of GlaxoSmithKline

MedImmune is the global biologics R&D arm of AstraZeneca

MedImmune is the global biologics research and development arm of AstraZeneca, focused on pioneering research and exploring novel mechanisms and pathways across key therapeutic areas.

MedImmune's MEDI8897 receives fast track designation by the FDA

MedImmune, the global biologics research and development arm of AstraZeneca, announced today that it has received fast track designation from the US Food and Drug Administration (FDA) for the development of MEDI8897.

9 April 2015Read in full

MedImmune and University Technical College Cambridge launch student Challenge Project

MedImmune, the global biologics research and development arm of AstraZeneca, and University Technical College (UTC) Cambridge have launched a six-week ‘Challenge Project’ for 60 Year Ten students, focused on the key challenges that a company like MedImmune faces in delivering new biological medicines to patients.

8 April 2015Read in full

First Maryland Regional Biotech Forum supported by MedImmune

Today and tomorrow, more than 400 leaders from life sciences companies, academic institutions, nonprofit organizations, investment funds and government entities across Maryland, Virginia and Washington, DC, will convene for the first Maryland Regional Biotech Forum.

30 March 2015Read in full

MedImmune establishes collaboration with São Paulo Research Foundation, Brazil

MedImmune and São Paulo Research Foundation (FAPESP) in Brazil will invest up to $2 million each to fund selected projects in cardiovascular and metabolic disease areas.

20 March 2015Read in full

MedImmune and Joslin Diabetes Center collaborate on advancing metabolic disease research

MedImmune, the global biologics research and development arm of AstraZeneca, and Joslin Diabetes Center, the world's largest diabetes research and clinical care organization, today announced a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity, and related metabolic disorders.

10 March 2015Read in full

MedImmune joins NIH Centers for Accerated Innovations Program as first pharma partner

Program aims to identify and translate innovations from the lab to patients.

20 February 2015Read in full

MedImmune and NIST partner to advance development of biological therapies

MedImmune, the global biologics research and development arm of AstraZeneca, and the US Department of Commerce’s National Institute of Standards and Technology (NIST) today announced the signing of a five-year agreement to jointly support research that will help advance drug discovery and manufacturing.

20 February 2015Read in full

MedImmune and University of Manchester partner to advance protein formulation science

MedImmune, the global biologics research and development arm of AstraZeneca, and the Centre of Excellence in Biopharmaceuticals (COEBP) at The University of Manchester today announced that they have entered into a new research collaboration to generate cutting-edge protein formulation science.

4 February 2015Read in full

Combacte-Magnet: another new project to revitalise antibotic development

Today 33 European academic partners and five pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the IMI antimicrobial resistance research programme New Drugs 4 Bad Bugs (ND4BB).

3 February 2015Read in full

First patient enrolled in the new Drugs 4 Bad Bugs Programme

Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca.

2 February 2015Read in full

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6